The precise molecular basis of retinoid embryopathy is yet unknown.
| INTRODUCTION
Isotretinoin, the most effective drug for the treatment of severe acne, is teratogenic. The majority of malformations induced by isotretinoin treatment during pregnancy primarily affect neural crest cells (NCCs) leading to craniofacial dysmorphic features involving cardiac, thymic and central nervous system structures (s1-s6), which have also been observed in pigtail monkeys exposed to ATRA during gestation (s7,s8). During craniofacial development, massive cell death occurs in vertebrates (s9). In the developing nervous system a well-regulated balance of apoptotic signalling ensures appropriate cell differentiation and maturation (s10,s11). Isotretinoin-treated NCCs often became rounded or spindle-shaped, separated from their neighbours, and frequently detached from the substrate or clumped together (s12).
Animal studies confirmed that administration of isotretinoin increases apoptosis of NCCs (s13-s15). It has recently been suggested that isotretinoin′s major desired and adverse drug effects including teratogenicity are related to apoptosis such as sebocyte and NCC apoptosis, respectively. [1, 2] The prodrug isotretinoin is intracellularly isomerized to ATRA (s16).
| ISOTRETINOIN AND P53-INDUCED APOPTOSIS
In sebocytes, increased expression of the pro-apoptotic proteins tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL-receptor 1 (DR4) and insulin-like growth factor-binding protein 3 (IGFBP3) have been related to isotretinoin-mediated sebocyte apoptosis. [1, 3] TRAIL-receptor 1 expression is upregulated by ATRA (s17). Increased expression of IGFBP3 has been reported in ATRAtreated NCCs. [4] Notably, p53 upregulates the expression of TRAIL, TRAIL-receptor 1, TRAIL-receptor 2 (DR5) and IGFBP3, respectively be especially susceptible to isotretinoin either due to their increased capacity for isomerization to ATRA (s16) or higher ATRA gradients due to decreased CYP26-mediated degradation of ATRA (s37).
| TREACHER COLLINS-, CHARGE-AND FETAL ALCOHOL SYNDROME
Treacher Collins syndrome (TCS), CHARGE (coloboma of the eye, heart defects, atresia of the choanae, retardation of growth/or development, genital and/or urinary abnormalities, ear abnormalities and deafness) syndrome and fetal alcohol syndrome resemble retinoid embryopathy and share overlapping craniofacial abnormalities (Table S1 ) (s38-s48). Abnormalities of the secondary palate were studied in an animal model in which features of TCS were induced by acute maternal exposure to isotretinoin (s49). TCS has been associated with enhanced activation of p53 (s37). [5] In an animal study, inhibition of p53-dependent apoptosis restored NCCs and prevented TCS craniofacial anomalies (s50). Overactivation of p53 induces features of CHARGE syndrome exhibiting loss of function gene mutations of the chromatin remodelling protein CHD7 [6] that is necessary for proper craniofacial development (s51). CHD7 binding to the TP53 promoter suppresses p53 expression. CHD7 loss in mouse NCC or samples from patients with CHARGE syndrome results in p53 activation. [7] Apoptosis also underlies ethanol-induced craniofacial malformations. [8] Upregulation of Siah1 by ethanol triggers apoptosis in NCCs through p38 MAPK-mediated activation of p53. [9] Thus, overactivation of p53 is the underlying mechanism for exaggerated NCC apoptosis promoting dysmorphic craniofacial features in the TCS and CHARGE syndrome as well as fetal alcohol spectrum disorders, which exhibit multiple overlapping features of isotretinoin embryopathy (Table S1 ).
| DEVELOPMENTAL STUDIES IN ZEBRAFISH
In addition, p53 plays a key role for NCC development in the zebrafish (s52). The zebrafish eif3ba mutant exhibits a hypogenesis of cranial NCCs associated with marked upregulation p53 and pronounced apoptosis in the cranial area (s52). The expression of the NC marker crestin was specifically reduced in cranial regions (s52). 
| CONCLUSION
Translational and clinical evidence derived from three neurocristopathies as well as developmental studies in the zebrafish allow the conclusion that isotretinoin upregulates the expression of p53 promoting NCC apoptosis. Thus, isotretinoin-induced p53-mediated apoptosis not only explains its desired sebum-suppressive effect via induction of sebocyte apoptosis [2, 10] but may also explain its harmful teratogenicity induced by exaggerated NCC apoptosis during embryogenesis.
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apoptosis, isotretinoin, p53, retinoic acid, retinoid embryopathy, teratogenicity F I G U R E 1 Working model of isotretinoin-induced sebum suppression and teratogenesis. Isotretinoin intracellularly isomerizes to all-trans retinoic acid (ATRA), which activates retinoic acid receptor (RAR)-mediated expression of p53 and HOX transcription factors. HOX activates the TP53 promoter. p53 promotes the expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptors (DR4/5) expression thereby stimulating the extrinsic and intrinsic (mitochondrial) pathway of apoptosis. p53 interaction with Bak promotes cytochrome c release and subsequent caspase-9 and caspase-3 activation. p53 attenuates prosurvival signalling via suppression of androgen receptor (AR), insulin-like growth factor 1 receptor (IGF1R), as well as survivin, a key negative regulator of caspase 3. p53 induces the expression of FoxO1, phosphatase and tensin homolog (PTEN), and sestrins which activate AMP-activated protein kinase (AMPK), a key negative regulator of mechanistic target of rapamycin complex 1 (mTORC1). Thus, ATRA-induced p53 over-expression promotes pro-apoptotic signalling and attenuates prosurvival signalling. Increased sebocyte apoptosis explains isotretinoin′s desired sebum-suppressive effect, whereas neural crest cell apoptosis during embryogenesis explains isotretinoin′s teratogenicity 
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Regression of diffuse B-cell lymphoma of the leg with intralesional gentian violet Abstract
In this case report, a patient of primary cutaneous diffuse B-cell lymphoma, leg type was treated with intralesional gentian violet as she was judged to be too medically fragile for conventional chemotherapy due to The patient was treated with radiation therapy due to multiple comorbidities, including coronary artery disease, diastolic heart failure, sleep apnoea and diabetes mellitus. She underwent radiation therapy of 30 Gray in 10 sessions, resulting in remission of the initial nodules.
However, three new nodules appeared outside the radiation field, which resolved with a single intravenous dose of rituximab. She was lost to follow-up until December 2015, when she presented with a 3-cm nodule on her right anterior leg ( Figure 1A) .
A punch biopsy of the nodule was performed, and gentian violet was introduced into the cavity and allowed to heal by secondary intention. The biopsy was consistent with recurrent PCLBCL of the leg ( Figure 1C,D) , but did contain infiltrating T lymphocytes ( Figure 1E ).
The tumor appeared negative for p53 (wild type) and also had very Gentian violet (crystal violet/hexamethyl pararosaniline) is a triphenylmethane dye.
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